Clinical Trials Browser

Advanced Malignant Solid Tumors

Carcinoma, Renal Cell

Muscle Invasive Bladder Cancer (MIBC)

Pancreatic Neoplasms

Uterine Cervical Neoplasms

Carcinoma, Squamous Cell, Head and Neck Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms, Papillomavirus Infections

Triple Negative Breast Neoplasms

Carcinoma, Renal Cell

Head and Neck Neoplasms

Small Cell Lung Carcinoma

Colorectal Neoplasms

Local Advanced Non-small Cell Lung Cancer

Colorectal Neoplasms

Nasopharyngeal Carcinoma

Oropharyngeal Neoplasms

Breast Neoplasms

Esophageal Squamous Cell Carcinoma

Breast Neoplasms, Triple Negative Breast Neoplasms

Small Cell Lung Carcinoma

Squamous Cell Carcinoma of Head and Neck

Locally Advanced Rectal Cancer

Uterine Cervical Neoplasms, Neoplasm Metastasis, Recurrence

Triple Negative Breast Neoplasms

Nasopharyngeal Carcinoma

Colorectal Neoplasms

Uterine Cervical Neoplasms

SCLC, Extensive Stage

Muscle-invasive Bladder Urothelial Carcinoma

Non-small Lung Cancer

Carcinoma, Non-Small-Cell Lung

Esophageal Squamous Cell Carcinoma

Advanced Lung Cancer

Resectable Stage II-III Non-Small Cell Lung Cancer (NSCLC)

Triple Negative Breast Neoplasms

Esophageal Squamous Cell Carcinoma

Turcot syndrome, Colorectal Neoplasms

Meningeal Carcinomatosis

Colonic Neoplasms

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ, Carcinoma, Transitional Cell

Carcinoma, Hepatocellular

Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

Carcinoma, Renal Cell

Triple Negative Breast Neoplasms

Biliary Tract Neoplasms

Skin Neoplasms

Clinical Trials

A Phase II Clinical Study Evaluating the Safety, Tolerability,Pharmacokinetics, and Preliminary Efficacy of JS212 andJS213 as Monotherapy and in Combination in Patients Withadvanced Malignant Solid Tumors

Neoadjuvant of Axitinib Plus PD-1 to Improve Disease Free Survival of Patients With Renal Cell Carcinoma

Probiotics Combined With Targeted Therapy Plus Immunotherapy in Bladder-Preserving Setting for Patients With MIBC

Surufatinib Plus mFOLFIRINOX and PD-1 Inhibitor as the Neoadjuvant Therapy for High-risk or Borderline Resectable Pancreatic Cancer

The Effect of Toripalimab Plus Radiotherapy in Patients With Operable Stage II-IIIA (N+) Non Small Cell Lung Cancer

Anti-PD-1 Antibody Combined With Histone Deacetylase Inhibitor in Patients With Advanced Cervical Cancer

Clinical Study of Therapeutic Immunological Agent for EBV-positive Advanced Malignant Tumors

(NeoScorch HN)

NEOTRIO-2

PLUTO

A Single-center Phase II Study to Investigate the Immune Maintenance Therapy Pattern in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma Who Have Achieved MPR After Neoadjuvant Immunotherapy Combined With Chemotherapy

Concurrent Chemoradiotherapy Combined With Toripalimab and Surufatinib in the Treatment of Limited-Stage Small Cell Lung Cancer

Neoadjuvant Dupilumab and Toripalimab in MSS CRC Subjects With Resectable Liver Metastases

InTRist

Combination Immunotherapy for the Treatment of Chemotherapy-refractory Metastatic MSS CRC

Gemcitabine + Docetaxel + Toripalimab Induction in Epstein-Barr Virus (EBV) Associated Nasopharyngeal Carcinoma(NPC)

Toripalimab in Combination With Standard Treatment for Human Papillomavirus (HPV) Positive Throat Cancer

Neoadjuvant Therapy Combined With Trastuzumab Rezetecan and Toripalimab for HR+/HER2-low Breast Cancer (NEOTORCH-BREAST 08)

TD-NEOE3V3

FACT-TN

Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction

SHINE

TORCH-iTNT

A Phase II Study of Utidelone With Toripalimab in Advanced Cervical Cancer

Toripalimab Combined With Platinum-based Chemotherapy With or Without H1 Receptor Antagonist in the Perioperative Treatment of Resectable Non-small Cell Lung Cancer

A Prospective, Multicenter, Open-label, Single-arm Phase II Clinical Study Evaluating the Efficacy and Safety of Spatially Fractionated Radiotherapy Combined With the PraG Strategy for the Treatment of Soft Tissue Sarcoma

Neoadjuvant Chemotherapy Combined With Toripalimab for TNBC (NEOTORCH-BREAST02)

Proton vs Photon IMRT in Locally Advanced Nasopharyngeal Carcinoma: A Phase III Trial

A Clinical Study of BioTTT001 in Combination With Toripalimab and Regorafenib in Patients With Colorectal Cancer

Toripalimab for High-risk Locally Advanced Cervical Cancer

Real-World Study of Toripalimab in Extensive-Stage Small Cell Lung Cancer

A Phase II Study of Toripalimab Plus RC48-ADC With Radiotherapy for Bladder Preservation in HER2-Positive Muscle-Invasive Bladder Cancer

Toripalimab Combined With SBRT for NSCLC

Stereotactic Body Radiotherapy With Sequential Iparomlimab and Tuvonralimab (QL1706) + Chemotherapy as Neoadjuvant Therapy in Patients With Resectable Non-small-cell Lung Cancer in China (LUNG-Nanjing01): a Single-arm, Single-centre, Phase 2 Trial

A Phase II Study of Toripalimab Plus Chemotherapy and Low-Dose Radiotherapy for Neoadjuvant Therapy-Refractory Esophageal Squamous Cell Carcinoma

JS004 Combined With Toripalimab and With Standard Chemotherapy Treat Patients With Advanced Lung Cancer

LungTime-C02

Sac-TMT Combined With Toripalimab for First-line Treatment of PD-L1 Positive a/mTNBC

Safety and Tolerability of a mRNA Vaccine Encoding Tumor-Specific Circular RNA Antigens in Combination With Anti-PD-1 Monoclonal Antibody in Patients With Advanced Solid Tumors

Stratified Treatment in Unresectable Locally Advanced ESCC Without Progression After Chemoimmunotherapy Induction Plus CCRT: Toripalimab Consolidation vs observation--a Prospective, Randomized, Controlled Phase III Multicenter Study

PICC

Immune Checkpoint Inhibitor Combined With Pemetrexed Intrathecal Injection for Leptomeningeal Metastasis From Solid Tumors

Immunotherapy (Toripalimab) for Reducing Recurrence Risk After Surgery for Mismatch Repair Deficient Stage IIB, IIC, or III Colon Cancer

OHAI-NMIBC-01

JS014 Combined With Toripalimab and TACE in Unresectable HCC: a Phase Ib Study

EC-CRT-008

Preoperative Therapy of Super-selective Tumor Artery Embolization Combined With Toripalimab and Axitinib in Advanced RCC

A Study of Sacituzumab Govitecan Plus Toripalimab Versus Toripalimab Plus Nab-Paclitaxel in PD-L1 Positive Advanced TNBC

Disitamab Vedotin Plus Lenvatinib and PD-1 Inhibitors for Treating HER2-positive Advanced Biliary Tract Cancer

Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy